Repeated biopsies in patients with prostate cancer on active surveillance: clinical implications of interobserver variation in histopathological assessment

被引:10
作者
Thomsen, Frederik B. [1 ]
Marcussen, Niels [2 ]
Berg, Kasper D. [1 ]
Christensen, Ib J. [3 ,4 ]
Vainer, Ben [5 ]
Iversen, Peter [1 ]
Brasso, Klaus [1 ]
机构
[1] Univ Copenhagen, Rigshosp, Dept Urol, Copenhagen Prostate Canc Ctr, DK-2100 Copenhagen, Denmark
[2] Univ Southern Denmark, Odense Univ Hosp, Dept Clin Pathol, Copenhagen, Denmark
[3] Univ Copenhagen, Rigshosp, Copenhagen Bioctr, Finsen Lab, DK-2100 Copenhagen, Denmark
[4] Univ Copenhagen, Rigshosp, Biotech Res & Innovat Ctr, DK-2100 Copenhagen, Denmark
[5] Univ Copenhagen, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark
关键词
prostate cancer; active surveillance; interobserver variation; re-biopsy; histopathology; progression; RADICAL PROSTATECTOMY; REPRODUCIBILITY; PROGRESSION; MANAGEMENT; CARCINOMA; PROGRAM;
D O I
10.1111/bju.12820
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the clinical implications of interobserver variation in the assessment of re-biopsies obtained during active surveillance (AS) of prostate cancer. Patients and Methods In all, 107 patients with low-risk prostate cancer with 93 diagnostic biopsy sets and 109 re-biopsy sets were included. The International Society of Urological Pathology 2005 Gleason scoring system was used for the histopathological assessment of all biopsies. Three different definitions of histopathological progression were applied. Unweighted and linear weighted Kappa (kappa) statistics were used to compare the interobserver agreement. Results The overall Gleason score agreement was 68.8% with a weighted kappa of 0.670. The interobserver agreement was 79.6% for meeting the AS selection criteria. According to the three progression definitions applied, overall agreement was between 80.7% and 89.0% with weighted kappa values of 0.746-0.791. Treatment recommendations would have changed in up to 10.1% (95% confidence interval 5.4-17.7%) of the 109 re-biopsy sets. Conclusion Kappa statistics showed strong agreement between the histological evaluations. However, up to 10% of patients on AS would receive a different treatment recommendation depending upon which histopathological evaluation of re-biopsies was used for treatment planning.
引用
收藏
页码:599 / 605
页数:7
相关论文
共 24 条
[21]   Guideline for the management of clinically localized prostate cancer: 2007 update [J].
Thompson, Ian ;
Thrasher, James Brantley ;
Aus, Gunnar ;
Burnett, Arthur L. ;
Canby-Hagino, Edith D. ;
Cookson, Michael S. ;
D'Amico, Anthony V. ;
Dmochowski, Roger R. ;
Eton, David T. ;
Forman, Jeffrey D. ;
Goldenberg, S. Larry ;
Hernandez, Javier ;
Higano, Celestia S. ;
Kraus, Stephen R. ;
Moul, Judd W. ;
Tangen, Catherine M. .
JOURNAL OF UROLOGY, 2007, 177 (06) :2106-2131
[22]   Active surveillance for clinically localized prostate cancer--A systematic review [J].
Thomsen, Frederik B. ;
Brasso, Klaus ;
Klotz, Laurence H. ;
Roder, M. Andreas ;
Berg, Kasper D. ;
Iversen, Peter .
JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (08) :830-835
[23]  
Thomsen FB, 2013, DAN MED J, V60
[24]   Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer [J].
Thomsen, Frederik Birkebaek ;
Christensen, Ib Jarle ;
Brasso, Klaus ;
Roder, Martin Andreas ;
Iversen, Peter .
BJU INTERNATIONAL, 2014, 113 (5B) :E98-E105